HC Wainwright Boosts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $60.00

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) had its price objective hoisted by equities researchers at HC Wainwright from $54.00 to $60.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 95.57% from the company's previous close. HC Wainwright also issued estimates for Kymera Therapeutics' Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.75) EPS and FY2029 earnings at ($0.57) EPS.

Several other research firms have also commented on KYMR. Stephens restated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. UBS Group reduced their price target on Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a research report on Monday, November 4th. Leerink Partners reaffirmed an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Guggenheim lifted their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a report on Friday, November 1st. Finally, BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a research note on Friday, December 6th. They issued a "market perform" rating and a $55.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $56.69.

Remove Ads

Kymera Therapeutics Trading Up 1.7 %

KYMR stock traded up $0.51 during trading on Friday, reaching $30.68. The stock had a trading volume of 608,129 shares, compared to its average volume of 579,649. The firm has a market cap of $1.99 billion, a PE ratio of -13.11 and a beta of 2.18. The stock's 50 day moving average is $38.81 and its two-hundred day moving average is $43.66. Kymera Therapeutics has a 52 week low of $29.07 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. On average, research analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,788 shares of company stock worth $455,202. Corporate insiders own 15.82% of the company's stock.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently made changes to their positions in the business. Blue Trust Inc. lifted its holdings in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares during the last quarter. Summit Investment Advisors Inc. raised its position in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock valued at $114,000 after purchasing an additional 504 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company's stock worth $1,649,000 after purchasing an additional 684 shares during the period. Finally, KBC Group NV increased its position in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.